Clinical Trials And ApprovalsNew cancer vaccine data shows a stronger Overall Survival (OS) trial in combination with PD1 compared to Keytruda alone, suggesting Moderna's treatment could be a significant advancement in cancer therapy.
Product Development And FundingModerna secures a funding agreement with Blackstone Life Sciences for up to $750 million to develop and commercialize the flu program, potentially reducing R&D costs and accelerating vaccine availability.
Vaccine EfficacyModerna's next-generation COVID-19 vaccine, mRNA-1283, demonstrates a higher immune response, indicating a potential improvement over existing vaccines, especially for populations over 65 years.